Detailed Information
Cited 182 time in 
Cited 177 time in 
Cited 177 time in
Metadata Downloads
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype
- Authors
- Oh, S.C.[Oh, S.C.]; Sohn, B.H.[Sohn, B.H.]; Cheong, J.-H.[Cheong, J.-H.]; Kim, S.-B.[Kim, S.-B.]; Lee, J.E.[Lee, J.E.]; Park, K.C.[Park, K.C.]; Lee, S.H.[Lee, S.H.]; Park, J.-L.[Park, J.-L.]; Park, Y.-Y.[Park, Y.-Y.]; Lee, H.-S.[Lee, H.-S.]; Jang, H.-J.[Jang, H.-J.]; Park, E.S.[Park, E.S.]; Kim, S.-C.[Kim, S.-C.]; Heo, J.[Heo, J.]; Chu, I.-S.[Chu, I.-S.]; Jang, Y.-J.[Jang, Y.-J.]; Mok, Y.-J.[Mok, Y.-J.]; Jung, W.[Jung, W.]; Kim, B.-H.[Kim, B.-H.]; Kim, A.[Kim, A.]; Cho, J.Y.[Cho, J.Y.]; Lim, J.Y.[Lim, J.Y.]; Hayashi, Y.[Hayashi, Y.]; Song, S.[Song, S.]; Elimova, E.[Elimova, E.]; Estralla, J.S.[Estralla, J.S.]; Lee, J.H.[Lee, J.H.]; Bhutani, M.S.[Bhutani, M.S.]; Lu, Y.[Lu, Y.]; Liu, W.[Liu, W.]; Lee, J.[Lee, J.]; Kang, W.K.[Kang, W.K.]; Kim, S.[Kim, S.]; Noh, S.H.[Noh, S.H.]; Mills, G.B.[Mills, G.B.]; Kim, S.-Y.[Kim, S.-Y.]; Ajani, J.A.[Ajani, J.A.]; Lee, J.-S.[Lee, J.-S.]
- Issue Date
- 3-May-2018
- Publisher
- Nature Publishing Group
- Citation
- Nature Communications, v.9, no.1
- Indexed
- SCIE
SCOPUS
- Journal Title
- Nature Communications
- Volume
- 9
- Number
- 1
- ISSN
- 2041-1723
- Abstract
- Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict. Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype (MP) and epithelial phenotype (EP), by analyzing genomic and proteomic data. Molecularly, MP subtype tumors show high genomic integrity characterized by low mutation rates and microsatellite stability, whereas EP subtype tumors show low genomic integrity. Clinically, the MP subtype is associated with markedly poor survival and resistance to standard chemotherapy, whereas the EP subtype is associated with better survival rates and sensitivity to chemotherapy. Integrative analysis shows that signaling pathways driving epithelial-to-mesenchymal transition and insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) pathway are highly activated in MP subtype tumors. Importantly, MP subtype cancer cells are more sensitive to inhibition of IGF1/IGF1R pathway than EP subtype. Detailed characterization of these two subtypes could identify novel therapeutic targets and useful biomarkers for prognosis and therapy response. © 2018 The Author(s).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.